Submissions for variant NM_007294.4(BRCA1):c.1953dup (p.Lys652fs)

dbSNP: rs80357753

Total submissions: 8

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA)	RCV000111739	SCV000299673	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 1	2016-09-08	reviewed by expert panel	curation	Variant allele predicted to encode a truncated non-functional protein.
Ambry Genetics	RCV000222152	SCV000275953	pathogenic	Hereditary cancer-predisposing syndrome	2023-10-27	criteria provided, single submitter	clinical testing	The c.1953dupG pathogenic mutation, located in coding exon 9 of the BRCA1 gene, results from a duplication of G at nucleotide position 1953, causing a translational frameshift with a predicted alternate stop codon (p.K652Efs*21). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration has been reported in a French Canadian family (Oros KK et al. Int. J. Cancer, 2004 Nov;112(3):411-9), as well as in a cohort of 115 women with breast cancer diagnosed at age 30 or younger (Evans DG et al. Br. J. Cancer, 2010 Mar;102:1091-8). This alteration was also identified in a large, worldwide study of BRCA1/2 mutation positive families (Rebbeck TR et al. Hum. Mutat., 2018 05;39:593-620). Of note, this alteration is also designated as 2072insG in published literature. In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Quest Diagnostics Nichols Institute San Juan Capistrano	RCV000505827	SCV000296408	pathogenic	not provided	2015-11-07	criteria provided, single submitter	clinical testing
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge	RCV000111739	SCV000325198	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 1	2015-10-02	criteria provided, single submitter	clinical testing
Color Diagnostics, LLC DBA Color Health	RCV000222152	SCV001354706	pathogenic	Hereditary cancer-predisposing syndrome	2020-01-15	criteria provided, single submitter	clinical testing	This variant inserts 1 nucleotide in exon 10 of the BRCA1 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.
Labcorp Genetics (formerly Invitae), Labcorp	RCV000496571	SCV001591060	pathogenic	Hereditary breast ovarian cancer syndrome	2024-05-08	criteria provided, single submitter	clinical testing	This sequence change creates a premature translational stop signal (p.Lys652Glufs*21) in the BRCA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA1 are known to be pathogenic (PMID: 20104584). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with breast or ovarian cancer (PMID: 25633036, 25802882, 26439132, 29215753). This variant is also known as c.1952_1953insG. ClinVar contains an entry for this variant (Variation ID: 54412). For these reasons, this variant has been classified as Pathogenic.
Breast Cancer Information Core (BIC) (BRCA1)	RCV000111739	SCV000144257	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 1	1999-04-06	no assertion criteria provided	clinical testing
Research Molecular Genetics Laboratory, Women's College Hospital, University of Toronto	RCV000496571	SCV000587172	pathogenic	Hereditary breast ovarian cancer syndrome	2014-01-31	no assertion criteria provided	research